Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | MLYCD | O95822 | 7/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29073464 | 0.82 | ALDH1A1 (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15672757 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CA12CA14CA7 | |
| SCHEMBL5783959 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CA12CA14CA7 | |
| SCHEMBL27929482 | 0.77 | TSHR (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7428898 | 0.77 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27424859 | 0.76 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL21609770 | 0.76 | CYP2D6 (0.46) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4822087 | 0.76 | GAA (0.41) | CYP2D6ALDH1A1 | |
| SCHEMBL14491873 | 0.76 | GAA (0.41) | CYP2D6ALDH1A1 | |
| SCHEMBL28737205 | 0.74 | ALDH1A1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-9861636-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-01-09 | — | — | US | disclosed |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138842-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-9532990-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-01-03 | — | — | US | disclosed |
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | CYP2D6 530/4885HDAC3 1448/4885HDAC1 1535/4885 |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | CYP2D6 530/4885HDAC3 1448/4885HDAC1 1535/4885 |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | CYP2D6 530/4885HDAC3 1448/4885HDAC1 1535/4885 |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | BTK, LCK, LYN | CYP2D6 530/4885HDAC3 1448/4885HDAC1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.